Technical Analysis for CYCC - Cyclacel Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 0.76 -5.00% -0.04
CYCC closed down 5.0 percent on Thursday, January 17, 2019, on 1.49 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical CYCC trend table...

Date Alert Name Type % Chg
Jan 17 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Jan 17 Wide Bands Range Expansion 0.00%
Jan 17 Upper Bollinger Band Touch Strength 0.00%
Jan 16 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -5.00%
Jan 16 New Uptrend Bullish -5.00%
Jan 16 Pocket Pivot Bullish Swing Setup -5.00%
Jan 16 Wide Bands Range Expansion -5.00%
Jan 16 Upper Bollinger Band Touch Strength -5.00%
Jan 15 1,2,3 Retracement Bearish Bearish Swing Setup 6.15%
Jan 15 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 6.15%

Older signals for CYCC ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Cyclacel Pharmaceuticals, Inc., a development-stage biopharmaceutical company, engages in the development and commercialization of mechanism-targeted drugs to treat human cancers and other serious diseases. The company's oncology development programs include its lead candidate, sapacitabine, which is in Phase III study that interferes with DNA synthesis and repair by causing single-strand DNA breaks that could induce arrest of the cell division cycle at the G2/M checkpoint; and second drug candidate, seliciclib, which is an orally-available CDK inhibitor that selectively inhibits a spectrum of enzyme targets, including CDK2/E, CDK2/A, CDK7, and CDK9 that are central to the process of cell division and cell cycle control. Its oncology development programs also comprise Plk1 Inhibitors, which is in preclinical stage for the treatment of cancer; CYC065, an orally-available 2nd generation inhibitor of CDK-2, -5, and -9 that helps in cancer cell growth, metastatic spread, and DNA damage repair; and Sapacitabine + Seliciclib, which is in Phase I trial for the treatment of cancer. The company's non-oncology programs include Cell Cycle Inhibitors, which completed Phase I trial for the treatment of autoimmune and inflammatory diseases. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.
Is CYCC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 1.93
52 Week Low 0.51
Average Volume 107,187
200-Day Moving Average 1.3083
50-Day Moving Average 0.8571
20-Day Moving Average 0.6711
10-Day Moving Average 0.7181
Average True Range 0.0757
ADX 28.61
+DI 21.7358
-DI 16.1321
Chandelier Exit (Long, 3 ATRs ) 0.6229
Chandelier Exit (Short, 3 ATRs ) 0.7371
Upper Bollinger Band 0.8005
Lower Bollinger Band 0.5417
Percent B (%b) 0.84
BandWidth 38.563552
MACD Line -0.0279
MACD Signal Line -0.0541
MACD Histogram 0.0262
Fundamentals Value
Market Cap 8.66 Million
Num Shares 11.4 Million
EPS -4.18
Price-to-Earnings (P/E) Ratio -0.18
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.91
Resistance 3 (R3) 0.92 0.89 0.89
Resistance 2 (R2) 0.89 0.85 0.88 0.88
Resistance 1 (R1) 0.82 0.82 0.81 0.81 0.87
Pivot Point 0.79 0.79 0.78 0.78 0.79
Support 1 (S1) 0.72 0.75 0.71 0.71 0.65
Support 2 (S2) 0.69 0.72 0.68 0.64
Support 3 (S3) 0.62 0.69 0.64
Support 4 (S4) 0.61